Cartesian Therapeutics, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Cartesian Therapeutics, Inc. (RNAC) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2025-03-13
- Cartesian Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00.
- Cartesian Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00.
- Cartesian Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-06-30 was $0.00.
- Cartesian Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Cartesian Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Cartesian Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $28.25M, a 43.42% increase from fiscal 2022.
- Cartesian Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $19.70M, a 20.12% increase from fiscal 2021.
- Cartesian Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $16.40M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $28.25M 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $28.25M 10-Q · filed 2024-11-07 | $33.95M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $28.25M 10-Q · filed 2024-08-08 | $33.95M derived: sum of 3 quarters · filed 2024-08-08 | $37.95M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $28.25M 10-Q · filed 2024-05-08 | $33.95M derived: sum of 2 quarters · filed 2024-05-08 | $37.95M derived: sum of 3 quarters · filed 2024-05-08 | $37.95M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $9.70M derived: sum of 2 quarters · filed 2024-03-07 | $9.70M derived: sum of 3 quarters · filed 2024-03-07 | $19.70M 10-K · filed 2024-03-07 |
| 2022-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $4.00M derived: sum of 2 quarters · filed 2023-11-13 | $14.00M 10-Q · filed 2023-11-13 | $24.00M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-17 | $10.00M 10-Q · filed 2023-08-17 | $20.00M derived: sum of 3 quarters · filed 2024-03-07 | $26.40M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $10.00M 10-Q · filed 2023-05-04 | $20.00M derived: sum of 2 quarters · filed 2024-03-07 | $26.40M derived: sum of 3 quarters · filed 2024-03-07 | $26.40M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $16.40M derived: sum of 2 quarters · filed 2024-03-07 | $16.40M derived: sum of 3 quarters · filed 2024-03-07 | $16.40M 10-K · filed 2024-03-07 |
| 2021-09-30 | $6.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.40M derived: sum of 2 quarters · filed 2022-11-03 | $6.40M 10-Q · filed 2022-11-03 | $6.40M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 10-K · filed 2023-03-02 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $16.35M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |